Glofitamab vs. real-world regimens in Chinese patients with third- or later-line relapsed/refractory diffuse large B-cell lymphoma: an external control study

Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin's lymphoma (NHL) worldwide, accounts for 39% and 44% of nodal and extranodal NHL cases in China, respectively[1][1]. Standard first-line treatment for DLBCL is chemo-immunotherapy with rituximab, cyclophosphamide,